Less than eight weeks after the launch of the French government's drugcost reduction policy (Marketletter June 18), the first list of drugs for which prices have been reviewed has appeared in the Official Journal. The list contains a total of 37 drug specialties.
The reductions, which have not been precisely indicated, are said to vary according to the product and mainly affect drugs which have been judged as inadequately effective. The cuts will come into force on September 1 this year for 34 items, on October 1 for one other and October 15 for the remaining two.
Some problems expected
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze